Medicinal Metal Ions and Metal-Based Complex

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1393

Special Issue Editors


E-Mail Website
Guest Editor
Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Sassari, Italy
Interests: analytical chemistry; bioinorganic chemistry; solution equilibria; metal complexes

E-Mail Website
Guest Editor
Department of Environmental and Life Science, Università degli Studi di Cagliari, Cagliari, Italy
Interests: analytical chemistry; solution equilibria; bioinorganic chemistry; chelating agents; toxic metal ions; environmental chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metals and metal complexes play a fundamental role in bioinorganic and medicinal chemistry. They can be essential in several biochemical processes for living organisms and fundamental in catalysis, materials synthesis, photochemistry, and biological systems. Additionally, the use of metals and their salts for medicinal purposes has been present throughout history.

The expanding knowledge surrounding their coordination chemistry is strongly dependent on understanding both thermodynamic and kinetic behavior in a given context, which is crucial for the design of new compounds for therapeutic and diagnostic use, such as with anticancer, diabetes, Parkinson’s and Alzheimer’s treatment, as well as PET and MRI.

In this Special Issue, Pharmaceuticals welcomes original research articles and reviews devoted to thermodynamics and kinetics complexation, solution equilibria, metals transport, homeostasis and toxicity, metal-based drugs in diagnosis and therapy, metal complex interactions with biomolecules, complexation processes in supramolecular chemistry, and analytical methods and sensors based on complexation equilibria within the field medicinal bioinorganic chemistry and its applications.

Dr. Rosita Cappai
Prof. Dr. Valeria M. Nurchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metal complexes
  • metal-based drugs
  • medicinal chemistry
  • chelating agents
  • solution equilibria

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 6612 KiB  
Article
Trimethyltin(IV) Bearing 3-(4-Methyl-2-oxoquinolin-1(2H)-yl)propanoate Causes Lipid Peroxidation-Mediated Autophagic Cell Death in Human Melanoma A375 Cells
by Marijana P. Kasalović, Dušan Dimić, Sanja Jelača, Danijela Maksimović-Ivanić, Sanja Mijatović, Bojana B. Zmejkovski, Simon H. F. Schreiner, Tobias Rüffer, Nebojša Đ. Pantelić and Goran N. Kaluđerović
Pharmaceuticals 2024, 17(3), 372; https://doi.org/10.3390/ph17030372 - 14 Mar 2024
Viewed by 1098
Abstract
A novel trimethyltin(IV) complex (Me3SnL), derived from 3-(4-methyl-2-oxoquinolin-1(2H)-yl)propanoate ligand, has been synthesized and characterized by elemental microanalysis, UV/Vis spectrophotometry, FT-IR and multinuclear (1H, 13C and 119Sn) NMR spectroscopies. Furthermore, the structure of the ligand precursor [...] Read more.
A novel trimethyltin(IV) complex (Me3SnL), derived from 3-(4-methyl-2-oxoquinolin-1(2H)-yl)propanoate ligand, has been synthesized and characterized by elemental microanalysis, UV/Vis spectrophotometry, FT-IR and multinuclear (1H, 13C and 119Sn) NMR spectroscopies. Furthermore, the structure of the ligand precursor HL was solved using SC-XRD (single-crystal X-ray diffraction). The prediction of UV/Vis and NMR spectra by quantum-chemical methods was performed and compared to experimental findings. The protein binding affinity of Me3SnL towards BSA was determined by spectrofluorometric titration and subsequent molecular docking simulations. Me3SnL has been evaluated for its in vitro anticancer activity against three human cell lines, MCF-7 (breast adenocarcinoma), A375 (melanoma) and HCT116 (colorectal carcinoma), and three mouse tumor cell lines, 4T1 (breast carcinoma), B16 (melanoma) and CT26 (colon carcinoma), using MTT and CV assays. The strong inhibition of A375 cell proliferation, ROS/RNS upregulation and robust lipid peroxidation lead to autophagic cell death upon treatment with Me3SnL. Full article
(This article belongs to the Special Issue Medicinal Metal Ions and Metal-Based Complex)
Show Figures

Figure 1

Back to TopTop